MARKERS OF EXFOLIATED BENIGN AND MALIGNANT BLADDER CELLS

脱落的良性和恶性膀胱细胞的标记物

• 批准号: 3191236
• 负责人: CARLOS CORDON-CARDO
• 金额: $ 12.95万
• 依托单位: MEMORIAL HOSPITAL FOR CANCER & ALLIED DI
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-04-10 至 1992-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3191236
• 关键词: antigen antibody reaction; bladder neoplasm; blood group antigens; cell differentiation; exfoliative cytology; flow cytometry; gene expression; histochemistry /cytochemistry; histopathology; immunochemistry; immunocytochemistry; metastasis; monoclonal antibody; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; oncogenes; receptor; tumor antigens; urinary bladder epithelium; urinary tract infection

Our overall objective is the evaluation of existing and newly developed monoclonal antibodies as potential tumor markers of exfoliated bladder epithelial cells, and to identify those markers of potential clinical value in detection of bladder tumors, predicting their behavior and response to therapy. The specific aims fall within three categories: 1) to rigorously test the sensitivity and specificity of binding to bladder tumor cells by a panel of 32 well characterized and presently available monoclonal antibodies to cell surface tumor-associated antigens, blood group related antigens, cytostructural antigens, oncogene- coded products, and growth factor receptors, (a) by immunohistochemistry on tissue sections of human bladder tumors, reactive or metaplastic urothelium in inflammatory processes and normal urothelium, (b) by immunocytochemistry on cytology smears of exfoliated bladder epithelial cells from patients with bladder tumors, cystitis and normal mucosa, (c) flow cytometry of bladder irrigation specimens and cell suspensions from resected tumors using dual parameter DNA/monoclonal antibody binding measurements and three parameter-dual laser DNA/double monoclonal antibody binding, 2) to correlate the antigenic phenotype of bladder tumors analyzed with (a) conventional histopathologic and cytologic features and flow cytometry parameters, (b) clinical course including tumor progression, metastases, and response to therapy, and 3) to establish a new subclassification of human bladder tumors based on immunophenotypic features reliable and useful in clinical management and prognosis. Our evaluation will involve comparative analysis of the cytology of exfoliated bladder epithelial cells, histology of resected tumors, flow cytometry of cell suspensions and bladder irrigation specimens, cystoscopy and biopsy findings; and a sequential evaluation of all the parameters mentioned above during follow- up of patients treated conservatively. These multiparameter analyses of human bladder tumors are expected to yield new markers for immunodiagnosis and important information about cellular differentiation and transformation.

我们的总体目标是评估现有的和新的 已开发的单抗可作为潜在的肿瘤标志物 脱落的膀胱上皮细胞，并鉴定这些标志物 在检测膀胱肿瘤方面具有潜在的临床价值， 预测他们的行为和对治疗的反应。 具体目标分为三类：1)严格 检测与膀胱癌结合的敏感性和特异性 由32个小组组成的单元格具有很好的特性，目前可用 抗细胞表面肿瘤相关抗原的单抗， 血型相关抗原，细胞结构抗原，癌基因- 编码产物和生长因子受体，(A)通过 人膀胱组织切片的免疫组织化学研究 炎症中的肿瘤、反应性或化生性尿路上皮 突起和正常尿路上皮，(B)免疫细胞化学方法 膀胱脱落上皮细胞的细胞学涂片 膀胱肿瘤、膀胱炎和正常粘膜患者，(C)血流 膀胱灌洗标本和细胞悬液的细胞学检测 用双参数DNA/单抗从切除的肿瘤中提取 抗体结合测量与三参数双激光 DNA/双单抗结合，2)关联 用(A)法分析膀胱肿瘤的抗原表型 常规组织病理学和细胞学特征及血流 细胞学参数，(B)包括肿瘤的临床病程 进展、转移和治疗反应，以及3) 建立一种新的人膀胱肿瘤亚类 免疫表型特征可靠、实用于临床的研究 管理和预后。 我们的评估将包括细胞学的比较分析 切除的膀胱上皮细胞的组织学观察 肿瘤、细胞悬液的流式细胞术和膀胱冲洗 标本、膀胱镜检查和活组织检查结果；以及 在跟踪过程中对上述所有参数进行评估- 保守治疗的患者比例上升。这些多参数 对人类膀胱肿瘤的分析有望产生新的 免疫诊断的标志物和有关的重要信息 细胞分化和转化。